Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 8/20 | 0.37 |
| ▸ | CTSS | P25774 | 5/20 | 0.36 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2909087 | 1.00 | ATM (0.37) | ATMCA1CA2CA7CTSK | |
| SCHEMBL25291413 | 1.00 | ATM (0.37) | ATMCA1CA2CA7CTSK | |
| SCHEMBL23833215 | 0.88 | CTSK (0.36) | ATMCA1CA2CA7CTSK | |
| SCHEMBL22006099 | 0.88 | CA2 (0.40) | ATMCA1CA2CA7CTSK | |
| SCHEMBL23833121 | 0.88 | CTSK (0.36) | ATMCA1CA2CA7CTSK | |
| SCHEMBL23833119 | 0.88 | CTSK (0.36) | ATMCA1CA2CA7CTSK | |
| SCHEMBL2013068 | 0.87 | CA1 (0.44) | ATMCA1CA2CA7CTSK | |
| SCHEMBL22409473 | 0.86 | CA1 (0.39) | ATMCA1CA2CA7CTSK | |
| SCHEMBL3676474 | 0.86 | CA1 (0.39) | ATMCA1CA2CA7CTSK | |
| SCHEMBL6333451 | 0.86 | CA1 (0.39) | ATMCA1CA2CA7CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | CBR3, BRIX1, CCNY | ATM 4075/4885CA1 3624/4885CA2 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.